

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 5

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5
obligations may continue. See Instruction 1(b).

☐ Form 3 Transactions Reported

☐ Form 4 Transactions Reported

1. Name and Address of Reporting Person*

Wiswell	Thomas	E.
-----	-----	-----
(Last)	(First)	(Middle)
234 Cuylers Lane		

(Street)		
Haverford,	Pennsylvania	19041
-----	-----	-----
(City)	(State)	(Zip)

2. Issuer Name and Ticker or Trading Symbol

Discovery Laboratories, Inc. (DSCO)

3. IRS Identification Number of Reporting Person, if an entity (Voluntary)

4. Statement for Month/Year

12/31/99

5. If Amendment, Date of Original (Month/Year)

6. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

☐ Director	☐ 10% Owner
☒ Officer (give title below)	☐ Other (specify below)
Executive Vice President of Clinical Research and Development	

7. Individual or Joint/Group Reporting
(check applicable line)

☒ Form Filed by One Reporting Person
☐ Form Filed by More than One Reporting Person

=====

Table I -- Non-Derivative Securities Acquired, Disposed of,
or Beneficially Owned

=====

1. Title of Security (Instr. 3)	2. Transaction Date (Month/ Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) ----- Amount (A) or (D) Price	5. Amount of Securities Beneficially Owned at the End of Issuer's Fiscal Year (Instr. 3 and 4)	6. Owner- ship Form: Direct (D) or Indirect (I) (Instr.4)	7. Nature of Beneficial Ownership (Instr. 4)
---------------------------------------	--	---	---	---	---	--

* If the form is filed by more than one Reporting Person, see Instruction 4(b)(v).

FORM 5 (continued)

Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conver- sion or Exer- cise Price of Deriv- ative Secur- ity	3. Trans- action Date (Month/ Day/ Year)	4. Trans- action Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) ----- (A) (D)	6. Date Exercisable and Expiration Date (Month/Day/Year) ----- Date Expira- tion cisable Date	7. Title and Amount of Underlying Securities (Instr. 3 and 4) ----- Amount or Number of Shares	8. Price of Deriv- ative Secur- ity (Instr. 5)	9. Number of Deriv- ative Secur- ities Bene- ficially Owned at End of Year (Instr. 4)	10. Owner- ship of Deriv- ative Secur- ity: Direct (D) or In- direct (I) (Instr. 4)	11. Nature of In- direct Owner- ship (Instr. 4)
Stock Option (right to buy)	\$1.380	9/30/1999	M(1)	A	9/30/1999 9/30/2009	Common Stock	45,000			
Stock Option (right to buy)	\$3.00	1/1/1999	M(2)	A	1/1/1999 1/1/2009	Common Stock	40,000			
Stock Option (right to buy)	\$4.44	6/16/1998	M(3)	A	6/16/1998 6/16/2008	Common Stock	20,493			
Stock Option (right to buy)	\$4.44	6/16/1998	M(4)	A	6/16/1998 6/16/2008	Common Stock	18,400	229,044	D	N/A

Explanation of Responses:

1. The option grants are subject to repurchase by Discovery upon the occurrence of certain events relating to the market price of the common stock of Discovery, the failure of Discovery to enter into certain collaboration agreements or a sale or merger of Discovery.

2. This option becomes vested as to 25% of the option shares on the date of the grant. The remaining 75% of the option shares are vested in three equal annual installments beginning with the first year anniversary of the date of the grant.

3. The Corporation's repurchase rights shall lapse and 100% of the option shares shall vest in the event the market capitalization of the Corporation exceeds \$75 million, determined over a 30 day average.

4. The Corporation's repurchase right shall lapse and 100% of the option shares shall vest in the event that the Corporation consummates a transaction having a total value of at least \$20 million involving the development, clinical testing, regulatory approval, manufacturing and/or marketing of a portfolio compound.

By: /s/ Thomas E. Wiswell February 11, 2000

**Signature of Reporting Person Date

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this form, one of which must be manually signed.
If space provided is insufficient, see Instruction 6 for procedure.